Thymosin Alpha-1 (Thymalfasin, Zadaxin)

Thymosin Alpha-1 (abbreviated Tα1 or TA-1) is a 28-amino-acid peptide hormone originally isolated by Allan Goldstein's group from thymosin fraction 5 — a bovine thymus extract — in the 1970s. The thymus gland is responsible for T-cell maturation, and thymic peptides play roles in immune development and maintenance. Thymosin Alpha-1 is now produced synthetically rather than extracted from animal tissue.^[1]

It is approved for clinical use in more than 35 countries — most prominently in China, Italy, the Philippines, and throughout Southeast Asia — under the brand name Zadaxin (manufactured by SciClone Pharmaceuticals). The primary approved indication is chronic hepatitis B, where it restores the T-cell response that chronic HBV infection suppresses. It is also studied in chronic hepatitis C, cancer adjuvant settings, and as sepsis immunotherapy.

In the United States, Thymosin Alpha-1 has never received standard FDA approval but has held orphan drug designation for certain indications. Its US regulatory history has been complicated: accessible through compounding pharmacies for years, restricted from compounding in 2023, then restored to compounding eligibility by HHS regulatory action in February 2026 — a sequence that explains much of the current US interest in the compound.

Important distinction: Thymosin Alpha-1 is not the same as Thymosin Beta-4 (or its research analog TB-500). The historical thymosin classification grouped peptides from thymic tissue extracts without implying functional similarity. The two molecules have different sequences, different receptors, different mechanisms, and different clinical applications.

The February 2026 regulatory change — what actually happened

The February 2026 HHS reclassification is the most significant US regulatory development for Thymosin Alpha-1 in years. What changed and what it means practically:

• What changed: HHS Secretary Robert F. Kennedy Jr. directed that Thymosin Alpha-1 be re-added to the 503A bulk drug substance list (the list of substances that compounding pharmacies may prepare for individual patient prescriptions). It had been removed from this list in 2023 following an FDA review questioning whether sufficient clinical evidence existed to support continued compounding availability.
• What the reclassification means practically: Licensed 503A compounding pharmacies (those serving individual patients with a prescription) can again prepare Thymosin Alpha-1. Licensed 503B outsourcing facilities (those producing larger quantities for healthcare facilities) may also be eligible depending on the specific language of the reclassification.
• What it does not mean: Thymosin Alpha-1 is not FDA-approved. The reclassification restored compounding access — it did not trigger an approval of any kind. The evidence standard for compounding eligibility is lower than the standard for drug approval.
• Political context: The Kennedy HHS has taken a notably permissive stance on compounding access for a range of peptides and biologics that had been restricted under the prior FDA framework. This is a politically charged area; the policy landscape may continue to evolve.

Thymosin Alpha-1 modulates immune function through several parallel mechanisms, all converging on enhancement of cellular (Th1-type) immunity:

• T-cell maturation and activation — Tα1 promotes differentiation of immature thymocytes into mature T cells and enhances T-cell receptor signaling in peripheral T cells. In chronic viral infections, this counters the exhaustion and anergy that impairs antiviral T-cell function.
• NK cell augmentation — Natural killer cell cytotoxicity is enhanced, supporting immune surveillance against virus-infected and transformed (malignant) cells.
• Dendritic cell maturation via TLR9 signaling — Tα1 activates dendritic cells through Toll-like receptor 9 (TLR9), the pattern recognition receptor for bacterial and viral DNA. This bridges innate and adaptive immunity, enhancing antigen presentation to T cells.
• Cytokine profile shift — Promotes interferon-gamma, IL-2, and other Th1 cytokines while having more modest effects on Th2 cytokines — making it potentially useful in situations where immune balance has tilted toward insufficient antiviral response.
• Regulatory T-cell modulation — In some models, Tα1 influences Treg function, which may partially explain its studied role in autoimmune contexts and cancer.

The critical framing word is modulates rather than boosts. Thymosin Alpha-1 restores or redirects immune function in contexts where it is dysregulated. In healthy adults with normal immune function, the same intervention does not clearly produce a net improvement — there is nothing obvious to restore.

The peer-reviewed literature on Thymosin Alpha-1 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

In approved clinical use: subcutaneous injection, typically twice weekly. Dosing depends on indication.

Thymosin Alpha-1 is one of the few peptides on this site with genuine international regulatory approval and a substantial clinical trial database. The 35+ country approval for chronic hepatitis B is real medicine with Phase 3 evidence; the February 2026 HHS reclassification restoring US compounding eligibility under RFK Jr. is a meaningful regulatory event that explains much of the current US community interest in the compound. The evidence is strongest for hepatitis B; defensible for sepsis and certain cancer-adjuvant contexts; thin for the general "immune support" use case that wellness marketing typically promotes.

For users interested in the post-viral recovery contexts (long-COVID, chronic fatigue, post-viral syndromes), the mechanism is plausible and the community use base is growing post-reclassification — but controlled human evidence in those specific populations remains limited. The clearest disconnect between marketing and evidence is the "general immune booster for healthy adults" framing: the compound's actual mechanism is restoration or redirection of dysregulated immune function, not enhancement of normal immune function. Working with a clinician familiar with Thymosin Alpha-1 (now substantially more accessible through 503A compounding pharmacies in 2026) is the appropriate framework for any specific therapeutic use case.